Publication

Een neurodegeneratieve tragedie. Pathogenese en therapie van amyotrofische laterale sclerose

Bongaerts, K. H. & Loonen, A. J. M., 29-Jun-2001, In : Pharmaceutisch Weekblad. 136, 26, p. 928-934 7 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Bongaerts, K. H., & Loonen, A. J. M. (2001). Een neurodegeneratieve tragedie. Pathogenese en therapie van amyotrofische laterale sclerose. Pharmaceutisch Weekblad, 136(26), 928-934.

Author

Bongaerts, K.H. ; Loonen, A.J.M. / Een neurodegeneratieve tragedie. Pathogenese en therapie van amyotrofische laterale sclerose. In: Pharmaceutisch Weekblad. 2001 ; Vol. 136, No. 26. pp. 928-934.

Harvard

Bongaerts, KH & Loonen, AJM 2001, 'Een neurodegeneratieve tragedie. Pathogenese en therapie van amyotrofische laterale sclerose', Pharmaceutisch Weekblad, vol. 136, no. 26, pp. 928-934.

Standard

Een neurodegeneratieve tragedie. Pathogenese en therapie van amyotrofische laterale sclerose. / Bongaerts, K.H.; Loonen, A.J.M.

In: Pharmaceutisch Weekblad, Vol. 136, No. 26, 29.06.2001, p. 928-934.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Bongaerts KH, Loonen AJM. Een neurodegeneratieve tragedie. Pathogenese en therapie van amyotrofische laterale sclerose. Pharmaceutisch Weekblad. 2001 Jun 29;136(26):928-934.


BibTeX

@article{90137a96eb84410f8cda4ae1dcf120a1,
title = "Een neurodegeneratieve tragedie. Pathogenese en therapie van amyotrofische laterale sclerose",
abstract = "Amyotrophic lateral sclerosis(ALS) is a chronic progressive neurological disorder characterised by degeneration of upper and lower motor neurons. Patients suffer from paresis and atrophy of the affected muscle groups and changes of myotactic reflexes. They usually pass away within 3-5 years, although some may live for over 10 years. An unequivocal pathogenetic mechanism has not yet been identified. Putative causes are found in a dysfunction of the glutamate transport system and/or a in change of the activity of the Cu/Zn superoxide dismutase. At present only rilusole is available to treat ALS. For the time being, a symptomatic treatment is the only therapy we have to offer in addition. Promising are the effects of certain neurotrophic factors in mice.",
keywords = "copper zinc superoxide dismutase, glutamate transporter, riluzole, amyotrophic lateral sclerosis, article, degenerative disease, disease course, human, muscle atrophy, myotatic reflex, paresis, pathogenesis",
author = "K.H. Bongaerts and A.J.M. Loonen",
year = "2001",
month = "6",
day = "29",
language = "Dutch",
volume = "136",
pages = "928--934",
journal = "Pharmaceutisch Weekblad",
issn = "0031-6911",
publisher = "Kon. Ned. Mij. ter Bevordering der Pharmacie (KNMP)",
number = "26",

}

RIS

TY - JOUR

T1 - Een neurodegeneratieve tragedie. Pathogenese en therapie van amyotrofische laterale sclerose

AU - Bongaerts, K.H.

AU - Loonen, A.J.M.

PY - 2001/6/29

Y1 - 2001/6/29

N2 - Amyotrophic lateral sclerosis(ALS) is a chronic progressive neurological disorder characterised by degeneration of upper and lower motor neurons. Patients suffer from paresis and atrophy of the affected muscle groups and changes of myotactic reflexes. They usually pass away within 3-5 years, although some may live for over 10 years. An unequivocal pathogenetic mechanism has not yet been identified. Putative causes are found in a dysfunction of the glutamate transport system and/or a in change of the activity of the Cu/Zn superoxide dismutase. At present only rilusole is available to treat ALS. For the time being, a symptomatic treatment is the only therapy we have to offer in addition. Promising are the effects of certain neurotrophic factors in mice.

AB - Amyotrophic lateral sclerosis(ALS) is a chronic progressive neurological disorder characterised by degeneration of upper and lower motor neurons. Patients suffer from paresis and atrophy of the affected muscle groups and changes of myotactic reflexes. They usually pass away within 3-5 years, although some may live for over 10 years. An unequivocal pathogenetic mechanism has not yet been identified. Putative causes are found in a dysfunction of the glutamate transport system and/or a in change of the activity of the Cu/Zn superoxide dismutase. At present only rilusole is available to treat ALS. For the time being, a symptomatic treatment is the only therapy we have to offer in addition. Promising are the effects of certain neurotrophic factors in mice.

KW - copper zinc superoxide dismutase

KW - glutamate transporter

KW - riluzole

KW - amyotrophic lateral sclerosis

KW - article

KW - degenerative disease

KW - disease course

KW - human

KW - muscle atrophy

KW - myotatic reflex

KW - paresis

KW - pathogenesis

M3 - Article

VL - 136

SP - 928

EP - 934

JO - Pharmaceutisch Weekblad

JF - Pharmaceutisch Weekblad

SN - 0031-6911

IS - 26

ER -

ID: 17492889